Please assess the completion status of the following clinical trial:

Trial Title: Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Laboratory-confirmed SARS-CoV-2 infection within 3 days (of proposed consent) or the presence of symptoms or signs providing a high probability of COVID-19 disease who have symptoms within 7 days prior to diagnosis as determined by Infectious Disease specialist or treating physicians.~* Outpatients. No previous hospitalization within the past 3 months.~* Subjects must have at least one of the following high-risk features for clinical deterioration:~  * Hypertension~ * Diabetes mellitus~ * Moderate to severe Chronic Obstructive Pulmonary Disease or asthma~ * Cancer patients who have received any immunosuppressive drugs within a year from enrollment.~ * Obesity as defined by a body mass index \> 30 kg/m2.~ * Living in a nursing home or long-term facility~ * Underlying serious heart condition as determined by the treating physician~ * Immunocompromised subject as defined by the treating physician or by the Infectious Disease specialist~ * Ability to provide informed consent by the patient or healthcare proxy.~ * Ability to return for repeated testing and observation to the hospital.~ * Patients must have adequate organ and marrow function measured within the last 30 days as defined below:~* platelets ≥100,000~* aspartate transaminase or alanine transaminase ≤3 times institutional upper limit of normal~* creatinine ≤ 1.5 times institutional upper limit of normal OR~* glomerular filtration rate ≥45 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2~Exclusion Criteria:~* Severe COVID-19 is defined by one or more of the following:~  * blood oxygen saturation ≤ 90%~ * partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300~ * lung infiltrates ≥ 50% within 24 to 48 hours~* Life-threatening COVID-19 is defined as one or more of the following:~  * respiratory failure~ * septic shock~ * multiple organ dysfunction or failure~* Weight less than 45 kg.~* Pregnant or breast-feeding females~* Subjects on dialysis or with creatinine clearance \< 45 ml/min~* Subjects who need antiviral administration due to severe viral diseases other than COVID-19, such as HIV, hepatitis B, and hepatitis C~* Existing Division of Microbiology and Infectious Disease Toxicity Scale for determining the severity of adverse events grade 3 or greater.~* Uncontrolled seizure disorder~* Subjects with reflux esophagitis after chronic pancreatitis and gastrectomy surgery.~* Patients with reflux esophagitis after surgery.~* Known allergy to Artemisia annua or camostat mesilate.~* Currently receiving any study medications for other indications.~* Concurrent use of medication that would cause moderate or severe due to drug-drug interactions with study medication.~Specifically:~* Patients receiving Artemisia annua tea may not be currently taking strong inducers of CYP2A6, including phenobarbital and rifampin.~* Receipt in the 12 hours prior to enrollment, or planned administration during the 14-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; or sotalol.~* Cancer patients receiving active immunosuppressive treatment cannot be enrolled unless they are on a treatment holiday with no antineoplastic treatment with 3 weeks of enrollment.~* Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption~* Subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening~* Enrollment on other experimental therapies for COVID-19.~* Inability to receive enteral medications~* Patients with psychiatric illness/social situations that would limit compliance with study requirements.~* Subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening~* Any other condition that in the opinion of the treating physician justifies exclusion from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Camostat mesilate (Type: ACTIVE_COMPARATOR): 100 mg tablet, 600 mg/day. Oral, 2 tablets three times a day, after a meal (600 mg total daily dose) Days 1-14.
- Camostat Placebo (Type: PLACEBO_COMPARATOR): Matched placebo
- Artemisia annua (Type: ACTIVE_COMPARATOR): Tea 225mg per bag,1350 mg/day. Oral, one 8 oz brewed tea (two bags) three times a day, Days 1-14.
- Artemisia annua Placebo (Type: PLACEBO_COMPARATOR): Matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy